Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PPID | Q08752 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878484 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1LMNAMMP8PPID | |
| SCHEMBL30929593 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1LMNAMMP8PPID | |
| SCHEMBL1878485 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1LMNAMMP8PPID | |
| SCHEMBL11581127 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMMP8PPIDALDH1A1 | |
| Hydrochloric Acid SCHEMBL27723691 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1LMNAMMP8PPID | |
| Hydrochloric Acid SCHEMBL27396543 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1LMNAMMP8PPID | |
| SCHEMBL7851021 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1LMNAMMP8POLB | |
| SCHEMBL27318750 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1LMNAMMP8POLB | |
| SCHEMBL27318747 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1LMNAMMP8POLB | |
| SCHEMBL7496252 | 0.82 | ALDH1A1 (0.53) | SMN1; SMN2L3MBTL1LMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | disclosed |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | THE BROAD INSTITUTE, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | THE BROAD INSTITUTE, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | THE BROAD INSTITUTE, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4188551-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| EP-3652179-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-05-20 | — | — | EP | disclosed |
| CN-110891954-A | Inhibitors of leucine-rich repeat kinase 2 | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019012093-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | LRRK2, PARK7, PINK1 | SMN1; SMN2 66/4885L3MBTL1 246/4885LMNA 1258/4885 |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | PNPO, THPO, PAH | SMN1; SMN2 380/4885L3MBTL1 4798/4885LMNA 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.